A Randomized, Multicenter, Double-blind Phase 3 Study Of Pd-0332991 (Oral Cdk 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With Er (+), Her2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment For Advanced Disease

Trial Profile

A Randomized, Multicenter, Double-blind Phase 3 Study Of Pd-0332991 (Oral Cdk 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With Er (+), Her2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment For Advanced Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2018

At a glance

  • Drugs Palbociclib (Primary) ; Letrozole
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PALOMA-2
  • Sponsors Pfizer
  • Most Recent Events

    • 24 Jul 2018 Results (n=1352) of pooled analysis of PALOMA studies (NCT00721409, NCT01740427 and NCT01942135) published in the European Journal of Cancer
    • 18 Jul 2018 Pooled data from PALOMA-1, PALOMA-2 and PALOMA-3 studies were published in the Journal of the National Cancer Institute.
    • 05 Jul 2018 Planned End Date changed from 15 Nov 2018 to 30 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top